Anti-ms4a4a antibodies and methods of use thereof
AssigneeAlector LLC
InventorsPhilip KONG, Herve RHINN, Tina SCHWABE, Angie YEE, Ilaria TASSI, Muhammad Abbas ALHAWAGRI, Arnon ROSENTHAL
Life of this patent
Estimating the term…
Abstract
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Claims30
1-28. (canceled)
An isolated nucleic acid comprising a nucleic acid sequence encoding an isolated antibody that binds to human MS4A4A, wherein the antibody comprises a heavy chain variable region and a light chain variable region,
- wherein the heavy chain variable region and the light chain variable region comprise an HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 comprising the amino acid sequences selected from the group consisting of SEQ ID NOs:4, 20, 38, 56, 75, and 86, respectively;
- SEQ ID NOs:5, 21, 39, 57, 76, and 87, respectively;
- SEQ ID NOs:6, 22, 40, 58, 76, and 88, respectively;
- SEQ ID NOs:7, 23, 41, 59, 77, and 89, respectively;
- SEQ ID NOs:8, 24, 42, 60, 78, and 90, respectively;
- SEQ ID NOs:9, 25, 43, 61, 76, and 91, respectively;
- SEQ ID NOs:10, 26, 44, 62, 79, and 93, respectively;
- SEQ ID NOs:7, 27, 45, 63, 77, and 89, respectively;
- SEQ ID NOs:7, 28, 46, 64, 77, and 89, respectively;
- SEQ ID NOs:11, 29, 47, 65, 80, and 93, respectively;
- SEQ ID NOs:12, 27, 45, 66, 77, and 89, respectively;
- SEQ ID NOs:13, 30, 48, 67, 76, and 94, respectively;
- SEQ ID NOs:14, 31, 49, 68, 81, and 95, respectively;
- SEQ ID NOs:16, 33, 51, 70, 77, and 97, respectively;
- SEQ ID NOs:17, 34, 52, 71, 83, and 98, respectively;
- SEQ ID NOs:19, 36, 54, 73, 84, and 100, respectively;
- SEQ ID NOs:7, 37, 55, 74, 85, and 89, respectively;
- SEQ ID NOs:142, 154, 168, 183, 197, and 210, respectively;
- SEQ ID NOs:144, 156, 170, 185, 199, and 212, respectively;
- SEQ ID NOs:144, 157, 171, 186, 81, and 213, respectively;
- SEQ ID NOs:145, 158, 172, 186, 81, and 214, respectively;
- SEQ ID NOs:146, 159, 173, 187, 200, and 215, respectively;
- SEQ ID NOs:147, 160, 174, 188, 201, and 216, respectively;
- SEQ ID NOs:148, 161, 175, 189, 202, and 217, respectively;
- SEQ ID NOs:149, 162, 176, 190, 203, and 218, respectively;
- SEQ ID NOs:150, 163, 177, 191, 204, and 219, respectively;
- SEQ ID NOs:151, 164, 178, 192, 205, and 220, respectively;
- SEQ ID NOs:147, 160, 179, 193, 206, and 221, respectively;
- SEQ ID NOs:152, 165, 180, 194, 207, and 222, respectively;
- SEQ ID NOs:153, 166, 181, 195, 208, and 223, respectively;
- SEQ ID NOs:151, 167, 182, 196, 209, and 224, respectively;
- SEQ ID NOs:304, 310, 316, 322, 328, and 334, respectively;
- SEQ ID NOs:305, 311, 317, 323, 329, and 335, respectively;
- SEQ ID NOs:306, 312, 318, 324, 330, and 336, respectively;
- SEQ ID NOs:307, 313, 319, 325, 331, and 337, respectively;
- SEQ ID NOs:308, 314, 320, 326, 332, and 338, respectively;
- SEQ ID NOs:309, 315, 321, 327, 333, and 339, respectively;
- SEQ ID NOs:15, 32, 50, 69, 82, and 96, respectively;
- SEQ ID NOs:18, 35, 53, 72, 77, and 99, respectively;
- and SEQ ID NOs:143, 155, 169, 184, 198, and 211, respectively.
34-36. (canceled)
Dependencies are inferred from the claim text.